Abemaciclib
An oral targeted cancer therapy that blocks proteins called CDK4 and CDK6, which cancer cells rely on to divide and multiply uncontrollably. It is primarily used in combination with hormonal therapies to treat certain types of hormone receptor-positive, HER2-negative breast cancer. Common side effects include diarrhea, which should be treated promptly, as well as low white blood cell counts that increase infection risk.
Berat Molekul
506,6000 g/mol
LogP
3,80
TPSA
75,00 Ų
Lipinski RO5
Lulus
Area Terapeutik
Mekanisme Kerja
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Struktur 2D
Cite this structure
Embed this structure
SMILES
CCN1CCN(Cc2ccc(Nc3ncc(F)c(-c4cc(F)c5nc(C)n(C(C)C)c5c4)n3)nc2)CC1
InChI
InChI=1S/C27H32F2N8/c1-5-35-8-10-36(11-9-35)16-19-6-7-24(30-14-19)33-27-31-15-22(29)25(34-27)20-12-21(28)26-23(13-20)37(17(2)3)18(4)32-26/h6-7,12-15,17H,5,8-11,16H2,1-4H3,(H,30,31,33,34)
Molecular Formula
C27H32F2N8
HBD / HBA
1 / 9
Ikatan yang Dapat Dirotasi
7
Atom Berat
37
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Pertanyaan yang Sering Diajukan
An oral targeted cancer therapy that blocks proteins called CDK4 and CDK6, which cancer cells rely on to divide and multiply uncontrollably. It is primarily used in combination with hormonal therapies to treat certain types of hormone receptor-positive, HER2-negative breast cancer. Common side effects include diarrhea, which should be treated promptly, as well as low white blood cell counts that increase infection risk.
Selectively inhibits cyclin-dependent kinases 4 and 6 (CDK4/6), blocking the phosphorylation of retinoblastoma protein and arresting the cell cycle at the G1/S transition to prevent cancer cell proliferation.
Yes, Abemaciclib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL3301610. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 46220502. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="abemaciclib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/abemaciclib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/abemaciclib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/abemaciclib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="abemaciclib"></drugfyi-drug>